Sibannac, Inc. Anticipates Surge In Psychedelic Tourism Following Presidential Executive Order Fast-Tracking Reserarch

SCOTTSDALE, AZ / ACCESS Newswire / April 23, 2026 / Sibannac, Inc. (OTCID:SNNC), a trailblazer in psychedelic tourism and plant-medicine experiences, welcomes President Trump’s executive order accelerating federal research into ibogaine, MDMA, psilocybin and related compounds.

Industry analysts and wellness travel operators predict a rapid expansion of a new niche: psychedelic-assisted wellness tourism tailored to veterans, law enforcement officers and first responders suffering from depression and PTSD.

Key points

• Market growth: Early market models from private sector analysts estimate the psychedelic-assisted wellness tourism market could reach $5-$15 billion annually by 2030, driven by faster clinical development, regulatory clarity, and growing clinical adoption for trauma-related conditions.

• Target segment opportunity: Veterans, law enforcement and first responders – groups with higher-than-average PTSD and treatment-resistant depression rates – could represent 10-25% of that market, implying potential annual revenues of roughly $500 million to $3.75 billion by 2030 for services specifically designed for these populations.

• Drivers: Federal research acceleration is expected to shorten timelines for approved therapeutic protocols and expand licensed clinic networks domestically and internationally.

“Federal commitment to rigorous research unlocks both clinical and commercial pathways,” said David Mersky, CEO of Sibannac. “When evidence-based psychedelic therapies are integrated into wellness travel programs, we can scale compassionate, high-quality care for veterans and first responders – and responsibly grow a significant new segment of the wellness tourism economy.”

About Sibannac

Sibannac, Inc. (OTCID:SNNC) is a forward-thinking lifestyle and wellness company curating psychedelic and plant-medicine tours and experiences both in the United States and abroad, to those seeking new treatment modalities for trauma-related conditions and general consciousness expansion.

For additional information and product updates, follow us and sign up for updates at:

Sibannic, Inc.
www.snncinc.com
x.com/sibannacinc
Media Contact: media@snncinc.com

Cautionary Note Regarding Forward-Looking Statements.

This press release contains statements that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of Sibannac, Inc. (the “Company”), its directors or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; (iii) growth strategy and operating strategy. The words “may,” “would,” “will,” “expect,” “estimate,” “can,” “believe,” “potential” and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control, and actual results may differ materially from those projected in the forward-looking statements as a result of various factors. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors, which are, in some cases, beyond the Company’s control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company’s expectations include, but are not limited to, those factors that are disclosed under the heading “Risk Factors” and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities.

SOURCE: Sibannac, Inc.

View the original press release on ACCESS Newswire